• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer

    8/28/23 7:00:57 AM ET
    $EDIT
    $MDNA
    $TNGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EDIT alert in real time by email

    Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions at leading public life-science corporations

    Mr. Caravella's appointment demonstrates Medicenna's continuing commitment to establish its presence in Boston, the leading biotechnology ecosystem

    TORONTO and HOUSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (NASDAQ:MDNA, TSX:MDNA), a clinical-stage immunotherapy company, today announced the appointment of Jeff Caravella as Chief Financial Officer (CFO). In this position, Mr. Caravella will lead Medicenna's financial strategy to support the Company's growth. This appointment underscores the Company's commitment to expanding its operations in Boston and follows the recent appointment of Mr. Brent Meadows as Chief Business Officer.

    "We are delighted to welcome Mr. Caravella as our new CFO. He brings a wealth of financial leadership experience to Medicenna, having successfully navigated the complex biotech financial landscape and driven growth strategies for prominent life science corporations," said Fahar Merchant, Ph.D., President and CEO of Medicenna. "His remarkable skills, combined with more than 20 years of profound financing and strategic expertise in the life sciences industry, will be invaluable to our objective of enhancing shareholder value. His nomination comes as the Company initiates a Phase 2 study with MDNA11, seeks partnership for bizaxofusp and Superkines, and expands its executive team with talented new hires in Boston."

    Mr. Caravella added: "I am excited to join Medicenna as it continues to advance a differentiated pipeline of next-generation immunotherapies through clinical development while also leveraging its unique Superkine platform for its drug discovery efforts. I look forward to working with the entire Medicenna team towards building out the company and contributing to our continued success."

    Mr. Caravella brings to Medicenna over 20 years of global healthcare, financial and operational experience. Most recently, he served as CFO at Biotheryx, where he led the finance, investor relations and operational functions and supported activities associated with an up to approximately $350 million collaboration with Incyte. Prior to Biotheryx, he served as Vice President of Finance at Tango Therapeutics (NASDAQ:TNGX), where he built and led the finance and accounting functions, successfully supported approximately $110 million in private financings and an approximately $350 million SPAC and PIPE transaction. Previously, Jeff held senior finance roles at Editas Medicine (NASDAQ:EDIT), Charles River Laboratories and Johnson & Johnson. During his 10-year tenure at Johnson & Johnson, he provided financial leadership on multiple licensing and option agreements with a potential cumulative value of over $1.4 billion and supported financial analysis, due diligence and integration of several acquisitions ranging in value from $100 million to $20 billion. Mr. Caravella earned his B.S. and M.B.A. from Syracuse University.

    About Medicenna

    Medicenna is a clinical-stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna's long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity thereby preferentially stimulating cancer-killing effector T cells and NK cells. Medicenna's IL-4 Empowered Superkine, bizaxofusp (formerly MDNA55), has been studied in 5 clinical trials including a Phase 2b trial for recurrent glioblastoma (GBM), the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and Orphan Drug status from the FDA and FDA/EMA, respectively. Medicenna's early-stage BiSKITs™ program, (Bifunctional SuperKine ImmunoTherapies) is designed to enhance the ability of Superkines to treat immunologically "cold" tumors.

    Forward Looking Statements

    This news release contains forward-looking statements within the meaning of applicable securities laws that relate to the future operations of the Company, plans and projections and other statements that are not historical facts, including, without limitation, statements on the Company's clinical development activities and potential, including with respect to MDNA11; the Company's commitment to expand its operations in Boston; and the potential benefits that may be realized as a result of new members of the management team. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expect", "believe", "seek", "potentially" and similar expressions. and are subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the risks detailed in the latest Annual Information Form and Annual Report on Form 20-F of the Company and in other filings made by the Company with the applicable securities regulators from time to time in Canada and the United States.

    The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date hereof and except as required by law, we do not intend and do not assume any obligation to update or revise publicly any of the included forward-looking statements.

    Further Information

    For further information about the Company please contact:

    Delphine Davan, Vice President, Investor Relations and Corporate Communications [email protected]

    Cell: 647-474-2641

     



    Primary Logo

    Get the next $EDIT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $EDIT
    $MDNA
    $TNGX

    CompanyDatePrice TargetRatingAnalyst
    Editas Medicine Inc.
    $EDIT
    4/28/2025$3.00Buy
    H.C. Wainwright
    Editas Medicine Inc.
    $EDIT
    12/16/2024Neutral → Underweight
    Analyst
    Editas Medicine Inc.
    $EDIT
    12/13/2024Buy → Neutral
    Chardan Capital Markets
    Editas Medicine Inc.
    $EDIT
    12/13/2024Buy → Hold
    Truist
    Editas Medicine Inc.
    $EDIT
    12/13/2024$11.00 → $3.00Buy → Hold
    Stifel
    Editas Medicine Inc.
    $EDIT
    12/11/2024$7.00 → $4.00Overweight → Equal Weight
    Wells Fargo
    Editas Medicine Inc.
    $EDIT
    11/25/2024$13.00 → $1.00Buy → Underperform
    BofA Securities
    Editas Medicine Inc.
    $EDIT
    11/6/2024In-line → Outperform
    Evercore ISI
    More analyst ratings

    $EDIT
    $MDNA
    $TNGX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tango Therapeutics to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025

      BOSTON, July 22, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that it will report second quarter 2025 financial results on August 5, 2025, before the open of the U.S. financial markets. The company does not intend to hold a conference call. About Tango TherapeuticsTango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more in

      7/22/25 7:00:00 AM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer

      BOSTON, June 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the Phase 1/2 trial of TNG462 and Revolution Medicines' daraxonrasib (RAS(ON) multi-selective inhibitor) or zoldonrasib (RAS(ON) G12D-selective inhibitor) in patients with MTAP-deleted and RAS mutant metastatic pancreatic or lung cancer. "Almost all MTAP-del pancreatic and approximately 30% of lung cancers have a co-occurring RAS mutation, and preclinical data show strong combination activity of TNG462 with either daraxonrasib or zoldo

      6/27/25 7:00:00 AM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June

      Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement supports development of a novel, in vivo approach to treating sickle cell disease and beta thalassemia. CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company, today shared new in vivo data demonstrating therapeutically relevant levels of HBG1/2 promoter editing in hematopoietic stem cells (HSCs) with a single dose of proprietary targeted lipid nanoparticle (tLNP) in non-human primates (NHPs). This clinically validated ap

      6/12/25 2:01:00 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EDIT
    $MDNA
    $TNGX
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Tango Therapeutics Inc.

      SCHEDULE 13G - Tango Therapeutics, Inc. (0001819133) (Subject)

      6/13/25 5:25:29 PM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Editas Medicine Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Editas Medicine, Inc. (0001650664) (Filer)

      6/12/25 6:28:39 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by Tango Therapeutics Inc.

      8-K - Tango Therapeutics, Inc. (0001819133) (Filer)

      6/6/25 4:02:30 PM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EDIT
    $MDNA
    $TNGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Editas Medicine with a new price target

      H.C. Wainwright initiated coverage of Editas Medicine with a rating of Buy and set a new price target of $3.00

      4/28/25 8:37:22 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine downgraded by Analyst

      Analyst downgraded Editas Medicine from Neutral to Underweight

      12/16/24 6:44:11 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine downgraded by Chardan Capital Markets

      Chardan Capital Markets downgraded Editas Medicine from Buy to Neutral

      12/13/24 8:14:41 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EDIT
    $MDNA
    $TNGX
    Leadership Updates

    Live Leadership Updates

    See more
    • Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights

      – Dose escalation ongoing in phase 1/2 trials of lead PRMT5 inhibitors TNG908 and TNG462; additional TNG908 clinical data expected 2024 – – Dose escalation ongoing in phase 1/2 trial of CoREST inhibitor TNG260 and pembrolizumab in patients with STK11 mutant solid tumors – – FDA Fast Track designation granted for TNG348, a novel USP1 inhibitor, for the treatment of BRCA1/2-mutant breast and ovarian cancer; phase 1/2 clinical trial initiation expected 1H 2024 – – Kanishka Pothula, partner at Nextech Ventures, appointed to Board of Directors, replacing Reid Huber, Ph.D., partner at Third Rock Ventures – – Strong cash position of $360 million; cash runway into 2026 expected to fund all clini

      11/8/23 7:00:00 AM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer

      TORONTO and HOUSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (NASDAQ:MDNA, TSX:MDNA), a clinical-stage immunotherapy company focused on the development of novel Superkines, today announced the appointment of Humphrey Gardner, M.D., as Chief Medical Officer (CMO) to lead the development strategy and execution of Medicenna's clinical programs. "We are thrilled to welcome Dr. Gardner as Medicenna's new CMO and member of our management team. Dr. Gardner holds remarkable leadership experiences advancing immune-based therapies for cancer and other diseases from the earliest stages of development through regulatory approvals," said Fahar Merc

      10/10/23 7:07:53 AM ET
      $MDNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Medicenna Announces Results of Annual and Special Meeting of Shareholders

      TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") ((NASDAQ, TSX:MDNA), a clinical-stage immuno-oncology company focused on the development of novel Superkines, today announced the voting results from the Company's annual and special meeting of shareholders held today, September 28, 2023 (the "Meeting"). Medicenna is pleased to announce that all of the nominees listed in the management information circular dated August 9, 2023 (the "Circular"), were elected as directors. Each director was elected with greater than 97% of the votes cast by shareholders present at the Meeting or represented by proxy. The results of the vote

      9/28/23 5:00:00 PM ET
      $MDNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EDIT
    $MDNA
    $TNGX
    Financials

    Live finance-specific insights

    See more
    • Tango Therapeutics to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025

      BOSTON, July 22, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that it will report second quarter 2025 financial results on August 5, 2025, before the open of the U.S. financial markets. The company does not intend to hold a conference call. About Tango TherapeuticsTango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more in

      7/22/25 7:00:00 AM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Editas Medicine Announces First Quarter 2025 Results and Business Updates

      Company to share in vivo preclinical data demonstrating the successful use of targeted lipid nanoparticles to deliver HBG1/2 promoter editing cargo to hematopoietic stem and progenitor cells (HSPCs) at ASGCT this week Company will also share in vivo preclinical proof of concept to upregulate expression of a target liver protein to meaningfully reduce a common disease-associated biomarker at ASGCT this week and TIDES next week Remains on track to declare two in vivo gene editing development candidates via gene upregulation, one in HSCs and one in liver, in mid-2025 Strong cash position with operational runway into the second quarter of 2027 CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIR

      5/12/25 4:30:00 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

      BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that it will report first quarter 2025 financial results on May 12, 2025, before the open of the U.S. financial markets. The company does not intend to hold a conference call. About Tango Therapeutics Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more info

      5/1/25 7:00:00 AM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EDIT
    $MDNA
    $TNGX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Rothenberg Mace bought $74,000 worth of shares (20,000 units at $3.70), increasing direct ownership by 178% to 31,250 units (SEC Form 4)

      4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

      11/18/24 7:20:03 PM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hopfield Jessica bought $253,868 worth of shares (45,000 units at $5.64), increasing direct ownership by 198% to 67,700 units (SEC Form 4)

      4 - Editas Medicine, Inc. (0001650664) (Issuer)

      5/14/24 4:17:23 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Boxer Capital, Llc bought $8,722,500 worth of shares (1,250,000 units at $6.98) (SEC Form 4) (Amendment)

      4/A - Tango Therapeutics, Inc. (0001819133) (Issuer)

      10/17/23 7:41:18 PM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EDIT
    $MDNA
    $TNGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Hopfield Jessica

      4 - Editas Medicine, Inc. (0001650664) (Issuer)

      6/10/25 4:19:40 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Scadden David

      4 - Editas Medicine, Inc. (0001650664) (Issuer)

      6/10/25 4:19:16 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Levy Elliott M.

      4 - Editas Medicine, Inc. (0001650664) (Issuer)

      6/10/25 4:18:49 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EDIT
    $MDNA
    $TNGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Tango Therapeutics Inc.

      SC 13G - Tango Therapeutics, Inc. (0001819133) (Subject)

      11/20/24 4:24:26 PM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Editas Medicine Inc.

      SC 13G/A - Editas Medicine, Inc. (0001650664) (Subject)

      11/12/24 2:30:25 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Tango Therapeutics Inc.

      SC 13D/A - Tango Therapeutics, Inc. (0001819133) (Subject)

      11/7/24 9:35:56 PM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care